Charles Schwab Investment Management Inc. Boosts Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Charles Schwab Investment Management Inc. increased its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,161,352 shares of the medical research company's stock after buying an additional 26,701 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.90% of NeoGenomics worth $19,139,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in NeoGenomics during the 4th quarter worth approximately $26,000. Versant Capital Management Inc raised its stake in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after acquiring an additional 1,142 shares during the period. Quarry LP bought a new stake in NeoGenomics during the 3rd quarter worth approximately $40,000. Smartleaf Asset Management LLC raised its stake in NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock worth $70,000 after acquiring an additional 2,787 shares during the period. Finally, Blue Trust Inc. raised its stake in NeoGenomics by 33.2% during the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after acquiring an additional 1,103 shares during the period. Hedge funds and other institutional investors own 98.50% of the company's stock.

NeoGenomics Price Performance

Shares of NEO stock traded down $0.07 on Friday, reaching $9.86. The company's stock had a trading volume of 2,530,820 shares, compared to its average volume of 810,734. The stock's fifty day simple moving average is $12.34 and its 200-day simple moving average is $14.57. NeoGenomics, Inc. has a 1 year low of $8.98 and a 1 year high of $19.12. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -15.90 and a beta of 1.28.

Remove Ads

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $172.00 million during the quarter, compared to analysts' expectations of $173.40 million. Analysts forecast that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Benchmark cut shares of NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a research note on Tuesday, December 10th. They set a "buy" rating and a $22.00 target price on the stock. Bank of America reduced their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. Needham & Company LLC reduced their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Finally, The Goldman Sachs Group reduced their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $19.60.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.